Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy

The Lancet Neurology

Volumn 14, Issue 3, 2015, Pages 318-328

  Liblau, Roland S ^a   Vassalli, Anne ^b   Seifinejad, Ali ^b   Tafti, Mehdi ^b,c  

^a France   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQB1 ANTIGEN; OREXIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ALLELE; ARTICLE; AUTOIMMUNITY; BRAIN CELL; CATAPLEXY; CELL POPULATION; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC ASSOCIATION; GENETICS; HUMAN; NARCOLEPSY; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BRAIN; IMMUNOLOGY; NERVE CELL NETWORK;

ANIMALS; BRAIN; CATAPLEXY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NERVE NET; NEUROPEPTIDES;

EID: 84923230468     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70218-2     Document Type: Article

References (112)

1. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
2. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
3. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
4. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
5. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
6. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
7. Thannickal TC, Siegel JM, Nienhuis R, Moore RY Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003, 13:340-351.
8. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
9. Olafsdóttir BR, Rye DB, Scammell TE, Matheson JK, Stefánsson K, Gulcher JR Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001, 57:1896-1899.
10. Hungs M, Lin L, Okun M, Mignot E Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001, 57:1893-1895.
11. Dauvilliers Y, Maret S, Tafti M Genetics of normal and pathological sleep in humans. Sleep Med Rev 2005, 9:91-100.
12. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998, 95:322-327.
13. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
14. Luca G, Haba-Rubio J, Dauvilliers Y, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res 2013, 22:482-495. the European Narcolepsy Network.
15. de Lecea L, Huerta R Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol 2014, 5:16.
16. Li J, Hu Z, de Lecea L The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol 2014, 171:332-350.
17. Lee MG, Hassani OK, Jones BE Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005, 25:6716-6720.
18. Kiyashchenko LI, Mileykovskiy BY, Maidment N, et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 2002, 22:5282-5286.
19. Mileykovskiy BY, Kiyashchenko LI, Siegel JM Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798.
20. Blouin AM, Fried I, Wilson CL, et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat Commun 2013, 4:1547.
21. Schuld A, Hebebrand J, Geller F, Pollmächer T Increased body-mass index in patients with narcolepsy. Lancet 2000, 355:1274-1275.
22. Poli F, Plazzi G, Di Dalmazi G, et al. Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep 2009, 32:1491-1497.
23. Beitinger PA, Fulda S, Dalal MA, et al. Glucose tolerance in patients with narcolepsy. Sleep 2012, 35:231-236.
24. Boutrel B, Steiner N, Halfon O The hypocretins and the reward function: what have we learned so far?. Front Behav Neurosci 2013, 7:59.
25. McGregor R, Wu MF, Barber G, Ramanathan L, Siegel JM Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level. J Neurosci 2011, 31:15455-15467.
26. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
27. Lutter M, Krishnan V, Russo SJ, Jung S, McClung CA, Nestler EJ Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci 2008, 28:3071-3075.
28. Mieda M, Williams SC, Sinton CM, Richardson JA, Sakurai T, Yanagisawa M Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. J Neurosci 2004, 24:10493-10501.
29. Muschamp JW, Dominguez JM, Sato SM, Shen RY, Hull EM A role for hypocretin (orexin) in male sexual behavior. J Neurosci 2007, 27:2837-2845.
30. D'Anna KL, Gammie SC Hypocretin-1 dose-dependently modulates maternal behaviour in mice. J Neuroendocrinol 2006, 18:553-566.
31. Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med 2010, 16:111-115.
32. Scott MM, Marcus JN, Pettersen A, et al. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res 2011, 222:289-294.
33. Burgess CR, Tse G, Gillis L, Peever JH Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010, 33:1295-1304.
34. Hasegawa E, Yanagisawa M, Sakurai T, Mieda M Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest 2014, 124:604-616.
35. Black SW, Morairty SR, Chen TM, et al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci 2014, 34:6485-6494.
36. Carter ME, Yizhar O, Chikahisa S, et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat Neurosci 2010, 13:1526-1533.
37. Nishino S Narcolepsy: pathophysiology and pharmacology. J Clin Psychiatry 2007, 68(suppl 13):9-15.
38. Wu MF, Gulyani SA, Yau E, Mignot E, Phan B, Siegel JM Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999, 91:1389-1399.
39. John J, Wu MF, Boehmer LN, Siegel JM Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004, 42:619-634.
40. Vassalli A, Dellepiane JM, Emmenegger Y, et al. Electroencephalogram paroxysmal θ characterizes cataplexy in mice and children. Brain 2013, 136:1592-1608.
41. Siegel JM, Nienhuis R, Fahringer HM, et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 1991, 252:1315-1318.
42. Oishi Y, Williams RH, Agostinelli L, et al. Role of the medial prefrontal cortex in cataplexy. J Neurosci 2013, 33:9743-9751.
43. Mignot E Genetic and familial aspects of narcolepsy. Neurology 1998, 50(suppl 1):S16-S22.
44. Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029-2033.
45. Mueller-Eckhardt G, Meier-Ewert K, Schendel DJ, Reinecker FB, Multhoff G, Mueller-Eckhardt C HLA and narcolepsy in a German population. Tissue Antigens 1986, 28:163-169.
46. Juji T, Satake M, Honda Y, Doi Y HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984, 24:316-319.
47. Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 2014, 37:19-25.
48. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686-699.
49. Todd JA, Bell JI, McDevitt HO HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987, 329:599-604.
50. Siebold C, Hansen BE, Wyer JR, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 2004, 101:1999-2004.
51. Pelin Z, Guilleminault C, Risch N, Grumet FC, Mignot E HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. Tissue Antigens 1998, 51:96-100. the US Modafinil in Narcolepsy Multicenter Study Group.
52. Nakayama J, Miura M, Honda M, Miki T, Honda Y, Arinami T Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 2000, 65:84-86.
53. Dauvilliers Y, Blouin JL, Neidhart E, et al. A narcolepsy susceptibility locus maps to a 5 Mb region of chromosome 21q. Ann Neurol 2004, 56:382-388.
54. Hor H, Bartesaghi L, Kutalik Z, et al. A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. Am J Hum Genet 2011, 89:474-479.
55. Moghadam KK, Pizza F, La Morgia C, et al. Narcolepsy is a common phenotype in HSAN IE and ADCA-DN. Brain 2014, 137:1643-1655.
56. Pedroso JL, Povoas Barsottini OG, Lin L, Melberg A, Oliveira AS, Mignot E A novel de novo exon 21 DNMT1 mutation causes cerebellar ataxia, deafness, and narcolepsy in a Brazilian patient. Sleep 2013, 36:1257-1259.
57. Winkelmann J, Lin L, Schormair B, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet 2012, 21:2205-2210.
58. Hor H, Kutalik Z, Dauvilliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010, 42:786-789.
59. Miyagawa T, Kawashima M, Nishida N, et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008, 40:1324-1328.
60. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708-711.
61. Han F, Faraco J, Dong XS, et al. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet 2013, 9:e1003880.
62. Zhernakova A, van Diemen CC, Wijmenga C Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009, 10:43-55.
63. Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011, 43:66-71.
64. Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013, 9:e1003270.
65. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004, 56:905-908.
66. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32:979-983.
67. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013, 136:2486-2496. the Narcoflu-VF study group.
68. Han F, Lin L, Li J, Dong XS, Mignot E Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol 2013, 73:560.
69. Seignalet J, Billiard M Possible association between HLA-B7 and narcolepsy. Tissue Antigens 1984, 23:188-189.
70. Langdon N, Welsh KI, van Dam M, Vaughan RW, Parkes D Genetic markers in narcolepsy. Lancet 1984, 2:1178-1180.
71. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33:1428-1430.
72. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7:e33536.
73. Szakács A, Darin N, Hallböök T Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013, 80:1315-1321.
74. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013, 31:1246-1254.
75. Black JL, Silber MH, Krahn LE, et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry 2005, 58:504-509.
76. Black JL, Avula RK, Walker DL, et al. HLA DQB1*0602 positive narcoleptic subjects with cataplexy have CSF lgG reactive to rat hypothalamic protein extract. Sleep 2005, 28:1191-1192.
77. Tanaka S, Honda Y, Inoue Y, Honda M Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 2006, 29:633-638.
78. Toyoda H, Tanaka S, Miyagawa T, Honda Y, Tokunaga K, Honda M Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 2010, 33:875-878.
79. Kawashima M, Lin L, Tanaka S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 2010, 33:869-874.
80. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010, 120:713-719.
81. Dauvilliers Y, Bauer J, Rigau V, et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol 2013, 70:1305-1310.
82. Liblau RS, Gonzalez-Dunia D, Wiendl H, Zipp F Neurons as targets for T cells in the nervous system. Trends Neurosci 2013, 36:315-324.
83. Noble JA, Valdes AM, Varney MD, et al. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 2010, 59:2972-2979. the Type 1 Diabetes Genetics Consortium.
84. Armangue T, Leypoldt F, Málaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014, 75:317-323.
85. Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP A functional autoantibody in narcolepsy. Lancet 2004, 364:2122-2124.
86. Katzav A, Arango MT, Kivity S, et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun 2013, 45:24-30.
87. Fairfax BP, Makino S, Radhakrishnan J, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet 2012, 44:502-510.
88. Fairfax BP, Humburg P, Makino S, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 2014, 343:1246949.
89. Al-Daccak R, Mooney N, Charron D MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 2004, 16:108-113.
90. Liu X, Zhan Z, Li D, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011, 12:416-424.
91. Orrù V, Steri M, Sole G, et al. Genetic variants regulating immune cell levels in health and disease. Cell 2013, 155:242-256.
92. Nathanson N The pathogenesis of poliomyelitis: what we don't know. Adv Virus Res 2008, 71:1-50.
93. Wu Y, Liu B, Lin W, et al. HPV16 E6 variants and HLA class II polymorphism among Chinese women with cervical cancer. J Med Virol 2007, 79:439-446.
94. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002, 8:1398-1404.
95. Sundqvist E, Buck D, Warnke C, et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 2014, 10:e1004084.
96. Birnbaum ME, Mendoza JL, Sethi DK, et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 2014, 157:1073-1087.
97. Lind A, Ramelius A, Olsson T, et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. J Autoimmun 2014, 50:99-106.
98. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
99. Masoudi S, Ploen D, Kunz K, Hildt E The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy. Vaccine 2014, 32:2980-2988.
100. Barker CI, Snape MD Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014, 14:227-238.
101. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009, 119:182-192.
102. Pignolet BS, Gebauer CM, Liblau RS Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. OncoImmunology 2013, 2:e27384.
103. Kreutzfeldt M, Bergthaler A, Fernandez M, et al. Neuroprotective intervention by interferon-γ blockade prevents CD8+ T cell-mediated dendrite and synapse loss. J Exp Med 2013, 210:2087-2103.
104. Yu DX, Marchetto MC, Gage FH Therapeutic translation of iPSCs for treating neurological disease. Cell Stem Cell 2013, 12:678-688.
105. Takahashi K, Yamanaka S Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
106. Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
107. Danjo T, Eiraku M, Muguruma K, et al. Subregional specification of embryonic stem cell-derived ventral telencephalic tissues by timed and combinatory treatment with extrinsic signals. J Neurosci 2011, 31:1919-1933.
108. Maroof AM, Brown K, Shi SH, Studer L, Anderson SA Prospective isolation of cortical interneuron precursors from mouse embryonic stem cells. J Neurosci 2010, 30:4667-4675.
109. Lupo G, Bertacchi M, Carucci N, Augusti-Tocco G, Biagioni S, Cremisi F From pluripotency to forebrain patterning: an in vitro journey astride embryonic stem cells. Cell Mol Life Sci 2014, 71:2917-2930.
110. Jeon K, Lim H, Kim JH, et al. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev 2012, 21:2642-2655.
111. Laterza C, Merlini A, De Feo D, et al. iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. Nat Commun 2013, 4:2597.
112. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.